Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 3/20 | 0.42 |
| ▸ | TNK2 | Q07912 | 8/20 | 0.41 |
| ▸ | MAP4K2 | Q12851 | 8/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.40 |
| ▸ | BMX | P51813 | 8/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1521590 | 0.89 | FGFR4 (0.42) | ABL1TNK2MAP4K2FGFR4BMX | |
| SCHEMBL1521796 | 0.86 | ABL1 (0.42) | ABL1TNK2MAP4K2FGFR4BMX | |
| SCHEMBL1521989 | 0.84 | ABL1 (0.46) | ABL1TNK2MAP4K2FGFR4BMX | |
| SCHEMBL1521636 | 0.84 | ABL1 (0.42) | ABL1TNK2MAP4K2FGFR4BMX | |
| SCHEMBL1522022 | 0.83 | ABL1 (0.39) | ABL1TNK2MAP4K2BMXBCR | |
| SCHEMBL1521530 | 0.82 | FGFR4 (0.40) | ABL1TNK2MAP4K2FGFR4BMX | |
| SCHEMBL1521629 | 0.79 | RAF1 (0.36) | ABL1TNK2MAP4K2BMXBCR | |
| SCHEMBL1521898 | 0.78 | FGFR4 (0.35) | ABL1TNK2MAP4K2FGFR4BMX | |
| SCHEMBL1521921 | 0.78 | ABL1 (0.47) | ABL1TNK2MAP4K2BMXBCR | |
| SCHEMBL1522030 | 0.78 | ABL1 (0.45) | ABL1TNK2MAP4K2BMXBCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118271-A1 | Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases | FLYNN DANIEL L | 2011-05-19 | — | — | US | claimed |
| US-7897762-B2 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2011-03-01 | — | — | US | claimed |
| EP-2063896-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2009-06-03 | — | — | EP | claimed |
| US-20090099190-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2009-04-16 | — | — | US | claimed |
| WO-2008033999-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-03-20 | — | — | WO | claimed |
| US-20110118271-A1 | Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases | FLYNN DANIEL L | 2011-05-19 | — | — | US | disclosed |
| US-7897762-B2 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090099190-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118271-A1 | Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases | BRAF, PRKDC, RAF1 | ABL1 936/4885TNK2 119/4885MAP4K2 22/4885 |
| US-20090099190-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | BRAF, PRKDC, RAF1 | ABL1 936/4885TNK2 119/4885MAP4K2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.